Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with Pfizer’s CDK4/6 Inhibitor Palbociclib
July 02 2019 - 8:00AM
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage
biotechnology company focused on discovering and developing novel
small molecule drugs for the treatment of cancer and other
life-threatening diseases, today announced treatment of the first
patient in a Phase 1/2 open-label clinical trial of the glutaminase
inhibitor telaglenastat (CB-839) in combination with Pfizer’s CDK
4/6 inhibitor palbociclib, also known as Ibrance®. The study will
evaluate the safety and anti-tumor activity of telaglenastat plus
palbociclib in patients with KRAS-mutated colorectal cancer (CRC)
and KRAS-mutated non-small cell lung cancer (NSCLC).
“Preclinical data suggest that telaglenastat and palbociclib
have synergistic activity in KRAS-mutated tumors, and may offer a
new approach to the challenges associated with treating
KRAS-mutated cancers,” said Susan Molineaux, Ph.D., president and
chief executive officer of Calithera. “We are excited to launch
this second clinical trial with Pfizer and are hopeful that the
telaglenastat-palbociclib combination could fill a significant
treatment gap for patients and medical professionals.”
Telaglenastat is designed to block glutamine consumption in
tumor cells. Genetic alterations, such as mutations in KRAS, can
cause cancer cells to increase metabolism of glutamine. In
preclinical studies with KRAS-mutated cancer models, telaglenastat
showed synergistic antitumor effects when used in combination with
CDK4/6 inhibitors, such as palbociclib, enhancing cell cycle arrest
and blocking cancer cell proliferation. The Phase 1/2
clinical trial (NCT03965845) will evaluate the safety and
anti-tumor activity of the telaglenastat plus palbociclib
combination in patients with locally advanced/metastatic
KRAS-mutated CRC and KRAS-mutated NSCLC that are refractory or
intolerant to standard therapies.
This is the second trial initiated by Calithera as part of an
ongoing clinical trial agreement with Pfizer. The first trial,
which is investigating the combination of telaglenastat with the
PARP inhibitor talazaporib in patients with renal cell carcinoma
(RCC), triple negative breast cancer (TNBC) and CRC began enrolling
patients in March 2019. As part of the agreement, Pfizer is
providing palbociclib and talazoparib, as well as financial
support.
About Telaglenastat
Telaglenastat is an investigational selective oral inhibitor
against human glutaminase, a critical enzyme that enables cancer
cells to utilize glutamine for metabolism and survival.Tumors
commonly exhibit metabolic alterations that increase their
dependence on glutamine. In pre-clinical studies, telaglenastat has
demonstrated synergistic antitumor activity when used in
combination with standard-of-care therapies. Telaglenastat in
combination with everolimus met the primary endpoint of improving
PFS compared to everolimus with placebo in ENTRATA, a randomized
Phase 2 clinical study. The compound is currently being
evaluated in multiple ongoing combination trials, including with
cabozantinib in the global, pivotal Phase 2 CANTATA
study.
About Calithera
Calithera Biosciences is a clinical-stage biopharmaceutical
company pioneering the discovery and development of targeted
therapies that disrupt cellular metabolic pathways to
preferentially block tumor cell growth and enhance immune-cell
activity. Driven by a commitment to rigorous science and a passion
for improving the lives of people impacted by cancer and other
life-threatening diseases, Calithera is advancing a pipeline of
first-in-clinic, oral therapeutics to meaningfully expand treatment
options available to patients. Calithera is headquartered in South
San Francisco, California. For more information about Calithera,
please visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Words such as "may," "will," "expect," "anticipate,"
"estimate," "intend," "poised" and similar expressions (as well as
other words or expressions referencing future events, conditions,
or circumstances) are intended to identify forward-looking
statements. These statements include those related to the success
of Calithera’s collaborations with Pfizer, the potential for
telaglenastat to be developed in combination with therapeutics,
such as palbociclib or talazoparib, to improve patient outcomes,
safety, tolerability and efficacy of telaglenastat, the overall
advancement of telaglenastat in clinical trials, the unmet need in
the treatment of patients with advanced disease, Calithera’s plans
to continue development of telaglenastat in combination with PARP
inhibitor talazoparib for the treatment of TNBC, RCC and CRC as
well as the related timing for clinical trials, and Calithera’s
plans to continue development of the combination of
telaglenastat plus palbociclib in CRC and NSCLC patients. Because
such statements are subject to risks and uncertainties, actual
results may differ materially from those expressed or implied by
such forward-looking statements. The product candidates that
Calithera develops may not progress through clinical development or
receive required regulatory approvals within expected timelines or
at all. In addition, clinical trials may not confirm any safety,
potency or other product characteristics described or assumed in
this press release. Such product candidates may not be beneficial
to patients or successfully commercialized. The failure to meet
expectations with respect to any of the foregoing matters may have
a negative effect on Calithera's stock price. Additional
information concerning these and other risk factors affecting
Calithera's business can be found in Calithera's most recent Annual
Report on Form 10-K filed with the Securities and Exchange
Commission, and other periodic filings with the Securities and
Exchange Commission at www.sec.gov. These forward-looking
statements are not guarantees of future performance and speak only
as of the date hereof, and, except as required by law, Calithera
disclaims any obligation to update these forward-looking statements
to reflect future events or circumstances.
SOURCE: Calithera Biosciences, Inc.
INVESTOR CONTACT: Jennifer McNealey
ir@Calithera.com650-870-1071
MEDIA CONTACT: Hannah Hurdle
hannahhurdle@sambrown.com 805-338-4752
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Apr 2023 to Apr 2024